These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24445015)

  • 1. Predictors of response to Infliximab in children with luminal Crohn's disease.
    Grover Z; Biron R; Carman N; Lewindon P
    J Crohns Colitis; 2014 Aug; 8(8):739-46. PubMed ID: 24445015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn's Disease.
    Ling J; Buurman D; Ravikumara M; Mews C; Thacker K; Grover Z
    Dig Dis Sci; 2018 Apr; 63(4):1003-1010. PubMed ID: 29480415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn's disease.
    Sazuka S; Katsuno T; Nakagawa T; Saito M; Saito K; Matsumura T; Arai M; Sato T; Yokosuka O
    Eur J Clin Nutr; 2012 Nov; 66(11):1219-23. PubMed ID: 23010687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
    J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with the loss of response to infliximab in patients with Crohn's disease.
    Sono K; Yamada A; Yoshimatsu Y; Takada N; Suzuki Y
    Cytokine; 2012 Aug; 59(2):410-6. PubMed ID: 22633084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.
    Vahabnezhad E; Rabizadeh S; Dubinsky MC
    Inflamm Bowel Dis; 2014 Apr; 20(4):606-13. PubMed ID: 24552827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
    Steenholdt C
    Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial.
    Buhl SS; Steenholdt C; Brynskov J; Thomsen OØ; Bendtzen K; Ainsworth MA
    BMJ Open; 2014 Dec; 4(12):e005887. PubMed ID: 25524543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment.
    Magro F; Rodrigues-Pinto E; Santos-Antunes J; Vilas-Boas F; Lopes S; Nunes A; Camila-Dias C; Macedo G
    J Crohns Colitis; 2014 Feb; 8(2):129-36. PubMed ID: 23932786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
    Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
    Gut; 2014 Jun; 63(6):919-27. PubMed ID: 23878167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neutrophil-lymphocyte ratio at 14th week predicts loss of response to 52-week infliximab therapy in patients with Crohn's disease].
    Qian G; Hongxia D; Jin LI
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Apr; 40(4):453-458. PubMed ID: 32895126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of concomitant elemental diet therapy in scheduled infliximab therapy in patients with Crohn's disease to prevent loss of response.
    Kamata N; Oshitani N; Watanabe K; Watanabe K; Hosomi S; Noguchi A; Yukawa T; Yamagami H; Shiba M; Tanigawa T; Watanabe T; Tominaga K; Fujiwara Y; Arakawa T
    Dig Dis Sci; 2015 May; 60(5):1382-8. PubMed ID: 25532505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique".
    Lecoutour A; Dupont C; Caldari D; Dumant C; Vanrenterghem A; Ruiz M; Duclaux-Loras R; Berthet S; Dimitrov G; Lacroix D; Duvant P; Roman C; Wagner AC; Bourmaud A; Viala J; Ruemmele FM; Pigneur B;
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1116-1125. PubMed ID: 38314896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
    J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
    Mantzaris GJ; Viazis N; Petraki K; Papamichael K; Theodoropoulos I; Roussos A; Karakoidas C; Koilakou S; Raptis N; Smyrnidis A; Agalos G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
    Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
    Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab therapy in children with Crohn disease previously treated with infliximab.
    Cozijnsen M; Duif V; Kokke F; Kindermann A; van Rheenen P; de Meij T; Schaart M; Damen G; Norbruis O; Pelleboer R; Van den Neucker A; van Wering H; Hummel T; Oudshoorn J; Escher J; de Ridder L;
    J Pediatr Gastroenterol Nutr; 2015 Feb; 60(2):205-10. PubMed ID: 25286063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease.
    Church PC; Guan J; Walters TD; Frost K; Assa A; Muise AM; Griffiths AM
    Inflamm Bowel Dis; 2014 Jul; 20(7):1177-86. PubMed ID: 24865777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial.
    Yoshida K; Fukunaga K; Ikeuchi H; Kamikozuru K; Hida N; Ohda Y; Yokoyama Y; Iimuro M; Takeda N; Kato K; Kikuyama R; Nagase K; Hori K; Nakamura S; Miwa H; Matsumoto T
    Inflamm Bowel Dis; 2012 Sep; 18(9):1617-23. PubMed ID: 22081474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.